Drug Interactions Affecting Oral Anticoagulant Use.

Area of Science:

• Pharmacology
• Drug Interactions
• Cardiovascular Medicine

Background:

• Oral anticoagulants (OACs) are crucial for managing atrial fibrillation and other cardiovascular conditions.
• Drug-drug interactions (DDIs) involving OACs are a significant cause of adverse drug reactions and healthcare burden.
• Warfarin and direct oral anticoagulants (DOACs) have distinct susceptibility profiles to DDIs.

Purpose of the Study:

• To review the mechanisms and clinical implications of DDIs with warfarin and DOACs.
• To provide guidance on managing and minimizing the risks associated with these DDIs.
• To highlight strategies for reducing bleeding risks in patients on concomitant antiplatelet/anticoagulant therapy.

Main Methods:

• Literature review of studies on warfarin and DOAC drug interactions.
• Analysis of cytochrome P450 (CYP) and P-glycoprotein (P-gp) pathways involved in OAC metabolism and transport.
• Examination of clinical guidelines for managing concomitant antiplatelet and anticoagulant use.

Main Results:

• Warfarin DDIs primarily involve CYP2C9 inhibitors/inducers, with contributions from CYP3A4 and CYP1A2.
• DOACs are mainly affected by P-gp modulators, and to a lesser extent, CYP3A4 inhibitors/inducers.
• Concomitant antiplatelet and anticoagulant therapy increases bleeding risk, necessitating careful duration management.

Conclusions:

• Awareness of specific DDI pathways for warfarin and DOACs is essential for safe prescribing.
• Avoiding strong CYP3A4/P-gp inducers/inhibitors with DOACs, as appropriate, can prevent DDIs.
• Minimizing the duration of combined antiplatelet/anticoagulant therapy is the primary strategy to mitigate bleeding risk.